[{"orgOrder":0,"company":"TWi Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TWiB Receives Canada Health Approval for AC-1101 Phase 1 CTA","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"TWi Biotechnology","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"TWi Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"TWi Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer\u2019s Xeljanz approved by the FDA for the treatment of children with arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc \/ Not Applicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Cadila Receives Tentative Approval from USFDA for Tofacitinib Extended-Release Tablets","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Extended Release Tablet","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Lifesciences \/ Not Applicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer Announces Positive Phase 3 Study Results for XELJANZ \u00ae in Ankylosing Spondylitis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Extended-Release Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Not Applicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer Shares Co-Primary Endpoint Results from Post-Marketing Required Safety Study of Xeljanz\u00ae in Rheumatoid Arthritis Patients","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","url1":"","url2":"","graph1":"Immunology","graph2":"Phase IV","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Pfizer Inc \/ Not Applicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Health Canada has Initiated a Safety Review On Xeljanz and Xeljanz XR (Tofacitinib), Used to Treat Arthritis and Ulcerative Colitis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","url1":"","url2":"","graph1":"Immunology","graph2":"Phase IV","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Pfizer Inc \/ Not Applicable"},{"orgOrder":0,"company":"Progenity","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Progenity Provides Preliminary Results from Key Studies for its Targeted Therapeutics Program","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Progenity","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Progenity \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Progenity \/ Not Applicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer\u2019s Tofacitinib Lowers Mortality in Covid-19 Pneumonia Trial in Brazil","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Not Applicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer\u2019s Xeljanz Receives European Marketing Approval to Treat Active Jia & Juvenile Psoriatic Arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc \/ Not Applicable"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VYNE Therapeutics Enrolls First Patient in Clinical Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"VYNE Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"VYNE Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"VYNE Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves Pfizer\u2019s XELJANZ\u00ae (Tofacitinib) for the Treatment of Active Ankylosing Spondylitis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc \/ Not Applicable"},{"orgOrder":0,"company":"Progenity","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Progenity Shares Two Poster Presentations on Treatment of Gastrointestinal Disorders at ECCO\u201922","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Progenity","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Progenity \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Progenity \/ Not Applicable"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VYNE Therapeutics Announces Positive Phase 1b Efficacy Data for FMX114 from Phase 1b\/2a Trial for the Treatment of Mild-to-Moderate Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"VYNE Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"VYNE Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"VYNE Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biora Therapeutics Shares Presentation of Patient Data Establishing Correlation Between Drug Levels in Colon and Patient Outcomes in Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biora Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VYNE Therapeutics Completes Enrollment in Phase 2a Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"VYNE Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"VYNE Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"VYNE Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VYNE Therapeutics Announces Results from its Phase 2a Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"VYNE Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"VYNE Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"VYNE Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biora Therapeutics Receives Pre-IND Feedback from FDA and Provides Update on Key Programs for 2023","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biora Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Children\u2019s Hospital Los Angeles","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$5.3 million","upfrontCash":"Undisclosed","newsHeadline":"Children\u2019s Hospital Los Angeles to Launch $5.3 Million NIH Study for First Clinical Trial for Down Syndrome Regression Disorder","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Funding","leadProduct":"Lorazepam","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Children\u2019s Hospital Los Angeles","amount2":0.01,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Controlled Substance","amount2New":0.01,"dosageForm":"","sponsorNew":"Children\u2019s Hospital Los Angeles \/ National Institutes of Health","highestDevelopmentStatusID":"12","companyTruncated":"Children\u2019s Hospital Los Angeles \/ National Institutes of Health"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus receives final and tentative Approval from the USFDA for Tofacitinib Tablets, 5 mg and 10 mg, respectively","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Lifesciences \/ Not Applicable"},{"orgOrder":0,"company":"TWi Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TWi Biotechnology Exploring Promising Treatment for Granuloma Annulare (GA)","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"TWi Biotechnology","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"TWi Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"TWi Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$8.0 million","upfrontCash":"Undisclosed","newsHeadline":"Biora Therapeutics Announces $8 Million Registered Direct Offering Priced at-the-Market Under Nasdaq Rules","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Public Offering","leadProduct":"Tofacitinib Citrate","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Biora Therapeutics","amount2":0.01,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.01,"dosageForm":"Liquid-filled Capsule","sponsorNew":"Biora Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"4","companyTruncated":"Biora Therapeutics \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$8.0 million","upfrontCash":"Undisclosed","newsHeadline":"Biora Therapeutics Announces Closing of $8 Million Registered Direct Offering of Common Stock and Warrants Priced At-the-Market Under Nasdaq Rules","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Public Offering","leadProduct":"Tofacitinib Citrate","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Biora Therapeutics","amount2":0.01,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.01,"dosageForm":"Liquid-filled Capsule","sponsorNew":"Biora Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"4","companyTruncated":"Biora Therapeutics \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biora Therapeutics Announces Submission of IND Application to the U.S. FDA for BT-600 Program","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Liquid-filled Capsule","sponsorNew":"Biora Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biora Therapeutics to Submit Updated IND Application for BT-600","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Liquid-filled Capsule","sponsorNew":"Biora Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biora Therapeutics Submits Updated IND Application for BT-600","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Liquid-filled Capsule","sponsorNew":"Biora Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biora Therapeutics Announces Initiation of Phase 1 Clinical Study of BT-600","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biora Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biora Therapeutics Announces Successful Completion of Single-Ascending Dose (SAD) Cohorts of Phase 1 Clinical Study of BT-600","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Biora Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biora Therapeutics Announces FDA Clearance of IND Application for Drug\/Device Combination BT-600 Targeting Treatment of Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Biora Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","amount":"$6.0 million","upfrontCash":"Undisclosed","newsHeadline":"Biora Therapeutics Announces $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Public Offering","leadProduct":"Tofacitinib Citrate","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0.01,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.01,"dosageForm":"Liquid-filled Capsule","sponsorNew":"Biora Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","amount":"$6.0 million","upfrontCash":"Undisclosed","newsHeadline":"Biora Therapeutics Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Private Placement","leadProduct":"Tofacitinib Citrate","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0.01,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.01,"dosageForm":"Liquid-filled Capsule","sponsorNew":"Biora Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCa Platform Development","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Liquid-filled Capsule","sponsorNew":"Biora Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biora Therapeutics Announces Completion of Multiple-Ascending Dose (MAD) Cohorts for Clinical Trial of BT-600","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biora Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biora Therapeutics Announces Positive Clinical Trial Results for BT-600","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biora Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biora Announces Supplemental Data from Phase 1 Trial of BT-600","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"","graph3":"Biora Therapeutics","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"","highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Biora Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"13","companyTruncated":"Biora Therapeutics \/ Not Applicable"}]
Find Clinical Drug Pipeline Developments & Deals for Tofacitinib Citrate
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target